“"Follow the Money:" Kevin Mahn on Stock Opportunities Beyond NVDA & MU”
ABVX is a prime acquisition target due to FDA approval progress and ongoing M&A trends.
Allergan. This stock has also been underperforming since the beginning of the year. It is a small biotechnology company, with a market value of only half a billion dollars. They are developing genetically modified T-cell therapies to treat cancer and autoimmune diseases.